Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil

Marco Colleoni, Karen N. Price, Monica Castiglione-Gertsch, Richard D. Gelber, Alan S. Coates, Aron Goldhirsch

Research output: Contribution to journalArticle

Abstract

Combined chemotherapy for early breast cancer with cyclophosphamide, methotrexate, and fluorouracil has low associated mortality, but related deaths were seen among women aged 65 years or older in International Breast Cancer Study Group trials.

Original languageEnglish
Pages (from-to)130-131
Number of pages2
JournalLancet
Volume354
Issue number9173
DOIs
Publication statusPublished - Jul 10 1999

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil'. Together they form a unique fingerprint.

  • Cite this